Phaseline

Targets › SLCX1

SLCX1: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Other; next expected readout Nov 2026.

Open in Phaseline: the race on SLCX1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Neurodawn PharmaceuticalY-4
combination of pregabalin (GABA analog) and riluzole (glutamate release inhibitor)
GABRA1, SLCX1Phase 2Postherpetic NeuralgiaNov 2026

Conditions

Postherpetic Neuralgia (1)

Modalities

small molecule (1)

Companies

Neurodawn Pharmaceutical (1)

Related targets

GABRA1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.